Oral Solid Dosage Contract Manufacturing Market

Oral Solid Dosage Contract Manufacturing Market Study by Tablets, Capsules, Powder, and Granules from 2024 to 2034

Analysis of Oral Solid Dosage Contract Manufacturing Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Oral Solid Dosage Contract Manufacturing Market Outlook

The oral solid dosage contract manufacturing market is estimated to expand to US$ 26,457.9 million in 2024. From 2024 to 2034, a CAGR of 4.4% is predicted for the oral solid dosage contract manufacturing sales. The oral solid dose contract manufacturing market is expected to achieve US$ 40,776.0 million by 2034.

With the demand for pharmaceutical outsourcing developing, the oral solid dosage contract manufacturing market has the potential for substantial expansion. Contract manufacturing organizations (CMOs) specializing in oral solid dosage forms should experience increased business as the pharmaceutical sector looks for economical and effective manufacturing options.

The oral solid dosage contract manufacturing market's promising future is due to improved production methods, technological improvements, and regulatory competence. Personalized medicine and the increase in pharmaceutical alliances are likely to propel the oral solid dose contract manufacturing market, offering plenty of opportunities for industry collaboration.

Dynamic Forces Reshaping the Oral Solid Dosage Contract Manufacturing Industry

Pharmaceutical businesses are focusing on their core capabilities while cutting costs and enhancing efficiency by outsourcing their manufacturing operations. The demand for oral solid dosage contract manufacturing is increasing due to this development.

Pharmaceutical businesses devote more resources to research and development by outsourcing their production activities. The focus on research and development promotes competitiveness in the oral solid dosage contract manufacturing market by facilitating the development of novel medications and formulations.

The pharmaceutical sector is known for its fierce rivalry and pressing need for quick product development. Contract manufacturing helps oral solid dosage contract manufacturing vendors swiftly match demand by utilizing the infrastructure and skills of seasoned manufacturers to shorten time-to-market.

Report Attributes Details
Estimated Market Value (2024E) US$ 26,457.9 million
Forecasted Market Value (2034F) US$ 40,776.0 million
Global Market Growth Rate (2024 to 2034) 4.4%
Tablets Prescription Type Segment Growth Rate (2024 to 2034) 4.9%
Tablets Disintegration Type Segment Growth Rate (2024 to 2034) 4.9%
Big Pharma or Biotech Segment Growth Rate (2024 to 2034) 5.4%
North America Market Share (2024) 4.1%
East Asia Market Share (2024) 10.3%
Key players in the Oral Solid Dosage Contract Manufacturing Market
  • Recipharm
  • Aenova Holding
  • Catalent
  • AbbVie
  • Patheon N.V. (Thermo Fisher Scientific)
  • NextPharma
  • Capsugel (Lonza Group AG)
  • Aurobindo Pharma Limited
  • Siegfried AG
  • Piramal Pharma Solutions
  • Corden Pharma
  • Kremoint Pharma Pvt Ltd.
  • HERMES PHARMA GmbH
  • Medipaams India Private Limited
  • Alpex Pharma
  • Abaris Healthcare Pvt Ltd
  • Ardena Holdings N.V
  • Aphena Pharma Solutions
  • Actiza Pharmaceutical Private Limited
  • Sunwin Healthcare PVT. LTD
  • Saffron Medicare PVT. LTD
  • Kosher Pharmaceuticals
  • Dr Reddy’s Lab
  • GlaxoSmithKline Plc
  • Boehringer Ingelheim BioXcellence

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Constraints to Success in Oral Solid Dosage Contract Manufacturing

Manufacturers of oral solid dosage contract manufacturing face difficulties due to strict regulatory requirements and changing compliance standards. It is difficult to meet different regulatory requirements, which leads to expenses and delays.

In the pharmaceutical business, maintaining constant product quality is essential. The oral solid dosage contract manufacturing producers must follow strict quality control procedures to guarantee the efficacy and safety of the oral solid dosage forms, which adds time and expense to the production process.

The possibility of intellectual property disputes between the client and the oral solid dosage contract manufacturing manufacturer is the key limitation. Implementing precise agreements and confidentiality safeguards to address issues regarding proprietary formulations and processes is crucial.

Country-wise Analysis

The oral solid dosage contract manufacturing market in North America to develop at a CAGR of 4.1% through 2034. Rising demand for oral solid dosage contract manufacturing in key countries, especially the United States and Canada, is the primary catalyst behind the spike. The United States tops the oral solid dosage contract manufacturing industry with an estimated share of 92.5% by 2034.

The oral solid dose contract manufacturing market in East Asia to advance at a 10.3% CAGR through 2034. China has emerged as the dominant force, with an 80.5% share in the oral solid dosage contract manufacturing industry in East Asia by 2034.

What Dynamics Shape the Oral Solid Dosage Contract Manufacturing Market in North America?

“Customization and Flexibility Cater to the Trend of Personalized Medicine”

The United States is increasingly inclined towards contract manufacturing services due to many variables, such as affordability, adaptability, and availability of cutting-edge technologies for formulation development. The United States oral solid dosage contract manufacturing industry is growing due to rising demand for specific formulations such as oral disintegrating and extended-release tablets. In 2024, the United States is going to command a 93.8% market share.

Attributes Details
United States Market CAGR 4.0%
United States Market Size (2024) US$ 8,520 million
Canada Market CAGR 5.2%
Canada Market Size (2024) US$ 341 million

Canada's advantageous location in the United States and Europe makes it a desirable outsourcing location for producing oral solid dosages and promoting international trade alliances and collaborations. Environmentally friendly efforts and sustainability practices are becoming more widespread in Canada, pushing oral solid dose contract manufacturers to adopt greener manufacturing techniques. In 2024, Canada is expected to own a 3.7% market share for oral solid dosage contract manufacturing.

What Trends Define the Oral Solid Dosage Contract Manufacturing Landscape in Asia Pacific?

“Asia Pacific Emerges as A Hub for Cost-Effective Oral Solid Contract Manufacturing”

China's market is driven by a changing regulatory environment that is in line with international quality standards and drawing in pharmaceutical companies. China is becoming a prominent location for oral solid dosage contract manufacturing due to its expanding knowledge of complicated formulations and a large pool of skilled workers, creating a strong and diverse business environment. In 2024, China is projected to possess a 93.8% oral solid dosage contract manufacturing share.

Attributes Details
China Market CAGR 10.4%
China Market Size (2024) US$ 317 million
Japan Market CAGR 9.5%
Japan Market Size (2024) US$ 36 million

The aging population in Japan contributes to the need for patient-centric formulations, which is changing the landscape of oral solid dosage contract manufacturing to meet the unique requirements of the senior population. The Japan oral solid dosage contract manufacturing market places a high value on quality control and good manufacturing practices, establishing the nation as a dependable center for contract production of oral solid doses. In 2024, Japan is expected to acquire a 3.7% oral solid dose contract manufacturing market share.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Category-wise Outlook

Based on the prescription type, the tablets segment is estimated to hold a 59.9% share by 2034. Simultaneously, the capsules segment is anticipated to secure a 33.8% share by 2034, contributing significantly to the market.

Based on disintegration type, the tablets segment marks its dominance, with a share of 59.9% by 2034. Followed by the capsules segment, grabbing a share of 33.8% by 2034.

What Factors Drive Tablets to Lead the Contract Manufacturing Market?

“Consumer Familiarity and Wide Acceptance of Tablets”

Tablets Prescription Type Details
Market CAGR (2024 to 2034) 4.9%
Market Share (2024) 56.9%
Capsules Prescription Type Details
Market CAGR (2024 to 2034) 4.0%
Market Share (2024) 35.2%

Tablets are widely used in contract manufacturing because their uniform release properties and precision dosing guarantee consistent therapeutic outcomes. Higher oral solid dosage contract manufacturing share is facilitated by mass production, made possible by the standardized nature of tablet manufacturing.

Tablets have superior stability, increased shelf life, and simpler packaging, which makes them a dependable option for contract manufacturing. In 2024, the tablet segment is expected to generate US$ 15,060.8 million in revenue.

Why Do Tablets Dominate Oral Solid Dosage Contract Manufacturing?

“Manufacturing Efficiency and Cost-Effectiveness Favor the Widespread Use of Tablet Production”

Tablets Disintegration Type Details
Market CAGR (2024 to 2034) 4.9%
Market Share (2024) 56.9%
Capsules Disintegration Type Details
Market CAGR (2024 to 2034) 4.0%
Market Share (2024) 35.2%

Standardized production procedures and cost-effectiveness increase the tablet segment's importance in the oral solid dosage contract manufacturing market. The tablet category leads in sales due to features that are easy for patients to use and administer.

Since they are so widely accepted and simple to formulate, tablets are the sector leader in the oral solid dose contract manufacturing market. In 2024, the tablet category is expected to be worth US$ 15,060.8 million.

Competitive Analysis

Key players in the oral solid dosage contract manufacturing market include Recipharm, Aenova Holding, Catalent, AbbVie, Patheon N.V. (Thermo Fisher Scientific), NextPharma, Capsugel (Lonza Group AG), Aurobindo Pharma Limited, Siegfried AG, Piramal Pharma Solutions, Corden Pharma, Kremoint Pharma Pvt Ltd., HERMES PHARMA GmbH, Medipaams, India Private Limited, Alpex Pharma, Abaris Healthcare Pvt Ltd, Ardena Holdings N.V, Aphena Pharma Solutions, Actiza Pharmaceutical Private Limited, Sunwin Healthcare PVT. LTD, Saffron Medicare PVT. LTD, Kosher Pharmaceuticals, Dr Reddy’s Lab, GlaxoSmithKline Plc, and Boehringer Ingelheim BioXcellence.

Due to a growing demand for outsourced pharmaceutical manufacturing services, the market is characterized by fierce competition among leading oral solid dosage contract manufacturing vendors. Reputable contract manufacturing organizations (CMOs) compete for market share by partnering strategically, growing their facilities, and advancing technology. The competition is stronger as cost-effectiveness, scalability, and quality compliance are prioritized more.

Prominent oral solid dosage contract manufacturing providers looking for dependable manufacturing partners are drawn to them by their broad experience, global reach, and varied service offerings. The oral solid dosage contract manufacturing market is characterized by a dynamic competitive landscape shaped by ongoing efforts to improve production capabilities, regulatory compliance, and innovation.

Notable Advancements

  • To expand its flagship large-scale oral dose form manufacturing facility in Winchester, Kentucky, Catalent, Inc. announced in May 2022 that it would invest US$ 175 million.
  • A new wing of the Riverview facility dedicated to producing High Potency Active Pharmaceutical Ingredients (HPAPIs) with Low Occupational Exposure Levels (OELs) was officially opened in June 2019, according to a statement released by Piramal Pharma Solutions (PPS), one of the leading CDMOs.
  • In August 2020, Pfizer Inc. and Gilead Sciences, Inc. announced a contract manufacturing services deal for Gilead's investigational antiviral medicine, remdesivir. The purpose of this collaboration is to increase the availability of investigational treatment for COVID-19 patients.
  • The Aenova Group installed the modern IMA Adapta 200 machine in January 2023, increasing its capacity to fill capsules at its Regensburg location.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Segmentation of Market Research

  • By Prescription Type:

    • Tablets
      • Over-the-Counter
      • Prescription
    • Capsules
      • Over-the-Counter
      • Prescription
    • Powders and Granules (MT)
      • Over-the-Counter
      • Prescription
  • By Disintegration Type:

    • Tablets
      • Immediate Release
      • Modified Release
      • Chewable Tablets
      • Effervescent Tablets
    • Capsules
      • Controlled Release
      • Enteric Release
      • Others
    • Powders and Granules (MT)
      • Uncoated Powders and Granules
      • Coated Granules
  • By End User:

    • Big Pharma or Biotech Companies
    • Small and Medium Size Pharma or Biotech Companies
    • Emerging or Virtual Pharma Companies
    • Nutraceutical Companies
  • By Region:

    • North America
    • East Asia
    • East Asia
    • South Asia and Pacific
    • Western Europe
    • Eastern Europe
    • The Middle East and Africa

- FAQs -

What was the Value of the Oral Solid Dosage Contract Manufacturing Market in 2019?

The global OSD contract manufacturing market was worth US$ 20,201.3 million in 2019.

What Is the Sales Outlook for Oral Solid Dosage Contract Manufacturing in 2024?

The sales of oral solid dosage contract manufacturing are likely to be valued at US$ 26,457.9 million in 2024.

What Is the Demand Forecast for Oral Solid Dosage Contract Manufacturing Market?

Demand for oral solid dosage contract manufacturing is expected to reach a market value of US$ 40,776.0 million by 2034.

What Is the Adoption Growth Projection for Oral Solid Dosage Contract Manufacturing Market?

The adoption of oral solid dosage contract manufacturing is projected to rise at a CAGR of 4.4% between 2024 and 2034.

At What CAGR Is the Oral Solid Dosage Contract Manufacturing Industry in North America Predicted to Grow?

The North America oral solid dosage contract manufacturing market is forecasted to expand at a CAGR of 4.1% from 2024 to 2034.

At What CAGR Is the Oral Solid Dosage Contract Manufacturing Market in East Asia Predicted to Grow?

The East Asia oral solid dosage contract manufacturing industry is forecast to expand at a CAGR of 10.3% through 2034.

- Also of Interest -

Oral Solid Dosage Pharmaceutical Market

Oral Solid Dosage Pharmaceutical Market Analysis By Dosage Form (Tablets, Capsules, Powders & Granules, Gummies, Lozenges & Pastilles) By Drug Release Mechanism (Immediate, Delayed & Controlled Release) By Distribution Channel & Region – Global Market Insights 2022 to 2032

Oral Health Ingredient Market

Oral Health Ingredient Market Analysis by Glycerin/Glycerol, Sorbitol, Calcium Carbonate, Sodium Lauryl Sulfate, Fluoride, Cetylpredinium Chloride, Chlorhexidine, and Ethanol from 2023 to 2033

Extended Oral Antibiotics Market

Extended Oral Antibiotics Market by Drug Type (Rifampin, Ciprofloxacin, Penicillin, Ampicillin), By Distribution Channel & Region - Global Forecast 2021-2031

Oral Hygiene Market

Oral Hygiene Market Analysis By Product (Toothpaste, Toothbrushes, Mouthwash, Dental Floss, Dental Accessories), By Distribution Channel (Hypermarkets/Supermarkets, Convenience Stores, Pharmacies & Drug Stores, Online Retail Stores) & Region - Global Market Insights 2023 to 2033

Oral Solid Dosage Contract Manufacturing Market

Schedule a Call